[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 81 of about 81
6. Inoue T, Yoshida M, Oowashi K, Yoshida T: [CD5-positive B-cell prolymphocytic leukemia]. Rinsho Ketsueki; 2010 Jan;51(1):80-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD5-positive B-cell prolymphocytic leukemia].
  • CD5 is a T-cell marker that is expressed in mature B cell malignancies and other B cell chronic lymphoproliferative disorders, but the biologic function of CD5 is unknown.
  • We report a 68-year-old woman with B-cell prolymphocytic leukemia (B-PLL) expressing CD5 antigen.
  • Hematological examination demonstrated a platelet count of 2.8 x 10(4)/microl and a white blood cell count of 19,900/microl with 69% PLL cells.
  • [MeSH-major] Antigens, CD5 / blood. Biomarkers, Tumor / blood. Leukemia, Prolymphocytic, B-Cell / blood. Leukemia, Prolymphocytic, B-Cell / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Female. Humans. Leukocyte Count. Platelet Count

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134145.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Ghosh S, Advani SH: T- cell prolymphocytic leukemia - a rare case. Indian J Cancer; 2005 Apr-Jun;42(2):104-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T- cell prolymphocytic leukemia - a rare case.
  • T- cell Prolymhocytic leukemia (T-PLL) is a rare mature post-thymic T-cell malignancy that is usually reported in the elderly and follows an aggressive course.
  • T- PLL is a rare T cell disorder with characteristic clinical and laboratory features.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Diagnosis, Differential. Humans. Male. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16141512.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


8. Singhal M, Raina V, Gupta R, Das P: T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J; 2010;3:4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report.
  • It includes acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); however T-cell prolymphocytic leukemia (T-PLL) has not been described earlier in relation to breast cancer and its therapy.
  • T-PLL is a rare chronic T-cell lymphoproliferative disease with a mature post-thymic T-cell immunophenotype and aggressive clinical course.
  • She was doing well on follow up until the completion of fifth year of her disease, when she presented with complaints of mild fever and weakness.
  • Peripheral blood examination revealed medium sized lymphoid cells, constituting almost 75% of total nucleated cell population.
  • Immunophenotying, established a diagnosis of post thymic T-cell prolymphocytic leukemia.
  • Unfortunately, both her malignancies progressed after an initial stable disease of two months.
  • CONCLUSION: Our case describes the potential of breast chemotherapy to cause grave second hematological malignancies of the T-cell lymphoid lineage, not described earlier.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):791-8 [19124806.001]
  • [Cites] BMC Cancer. 2007;7:152 [17683622.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):292-300 [17159192.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4179-91 [15961765.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1745-51 [1594016.001]
  • [Cites] J Clin Oncol. 1985 Dec;3(12):1640-58 [3906049.001]
  • [Cites] Clin Breast Cancer. 2003 Oct;4(4):273-9 [14651772.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2722-30 [8874333.001]
  • (PMID = 20076807.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806858
  •  go-up   go-down


9. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Crisostomo RH, Fernandez JA, Caceres W: Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. Leuk Res; 2007 May;31(5):699-701
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.
  • We report a case of a 64-year-old white female patient, who presented with symptomatic anemia (Hgb: 6.8g/dl), thrombocytopenia (platelets: 94,000/mcl) and leukocytosis (WBC: 156,000/mcl).
  • Peripheral blood smear revealed markedly increased white blood cell count with predominance of atypical lymphoid cells of intermediate size, moderately dense chromatin, and prominent large single nucleoli.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Leukemia, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997373.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D: IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia; 2006 Jul;20(7):1231-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
  • B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis.
  • To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL.
  • [MeSH-major] Antigens, CD38 / genetics. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Membrane Glycoproteins / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642047.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


12. Khot A, Dearden C: T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther; 2009 Mar;9(3):365-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia is a rare post-thymic lymphoid disorder, which has distinctive clinical, morphologic, immunophenotypic and cytogenetic features.
  • However, responses are transient and allogeneic hematopoietic progenitor-cell transplantation remains the only potential curative option.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / genetics. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / genetics. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Drug Administration Schedule. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Stem Cell Transplantation. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275513.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 46
  •  go-up   go-down


13. Dearden CE: T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S239-43
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia is a rare postthymic malignancy with distinctive clinical, morphologic, immunophenotypic, and cytogenetic features.
  • Nevertheless, responses are relatively short, and the only potential curative treatment is allogeneic stem cell transplantation.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Medical Oncology / methods. Middle Aged. Pentostatin / therapeutic use. Stem Cell Transplantation / methods. Transplantation, Homologous / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778847.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab
  • [Number-of-references] 38
  •  go-up   go-down


1
Advertisement
4. Zhang YN, Zhou XG, Zhang SH, Wang P, Zhang CH, Huang SF: [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Apr;34(4):193-7
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].
  • OBJECTIVE: To describe the relative frequency, morphologic features, immunophenotype and clinical data of different types of B-cell non-Hodgkin lymphoma (B-NHL) and to evaluate the practical application of the 2001 World Health Organization (WHO) classification of lymphoid neoplasms.
  • Diffuse large B-cell lymphoma, extranodal marginal zone lymphoma and follicular lymphoma were the commonest subtypes, accounting for 51.2% (189 cases), 14.9% (55 cases) and 10.6% (39 cases) of all cases respectively.
  • B-cell prolymphocytic leukemia and hairy cell leukemia were not identified.
  • When comparing the diagnosis based on morphologic examination alone with the diagnosis based on both morphology and immunophenotype, there was a 80% concordance rate.
  • Immunohistochemical study was helpful in reaching the correct diagnosis in many cases and could improve the overall diagnostic accuracy by about 20%.
  • CONCLUSIONS: Amongst cases of B-NHL, diffuse large B-cell lymphoma is the commonest subtype, followed by MALToma and follicular lymphoma.
  • While morphologic examination forms the basis for lymphoma diagnosis, immunohistochemical study also plays an important role in further subtyping.
  • A combination of both modalities are sufficient for arriving at an accurate diagnosis in most cases of B-NHL, in keeping with the recommendation of the 2001 WHO classification of lymphoid neoplasms.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / classification

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091170.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD79
  •  go-up   go-down


15. Valbuena JR, Herling M, Admirand JH, Padula A, Jones D, Medeiros LJ: T-cell prolymphocytic leukemia involving extramedullary sites. Am J Clin Pathol; 2005 Mar;123(3):456-64
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia involving extramedullary sites.
  • T-cell prolymphocytic leukemia (T-PLL) can involve extramedullary sites, but the diagnosis is usually established by examination of blood and bone marrow.
  • Cytologically, the T-PLL cells were round (n = 16) or Sezary cell-like (n = 3).
  • Immunostaining for T-cell leukemia-1 (TCL-1) was positive in specimens from 9 (64%) of 14 patients.
  • TCL-1 expression can aid in diagnosis at extramedullary sites.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, T-Cell / pathology. Lymphoid Tissue / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716243.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Foucar K: Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome. Am J Clin Pathol; 2007 Apr;127(4):496-510
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome.
  • The 2005 Society for Hematopathology/European Association for Haematopathology Workshop Session 1 was devoted to case presentations with discussions of 3 types of mature T-cell leukemias--T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome.
  • The application of clinical, morphologic, immunophenotypic, and genetic studies to the assessment and characterization of these 3 disorders is presented, along with specific diagnostic recommendations and differential diagnostic considerations.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis. Sezary Syndrome / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD / metabolism. Chromosome Aberrations. Diagnosis, Differential. Humans. Immunophenotyping

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369126.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


17. Nusz KJ, Pang NK, Woog JJ: Periorbital edema as the initial presentation of T-cell prolymphocytic leukemia. Ophthal Plast Reconstr Surg; 2006 May-Jun;22(3):215-6
MedlinePlus Health Information. consumer health - Eyelid Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periorbital edema as the initial presentation of T-cell prolymphocytic leukemia.
  • Laboratory tests revealed T-cell prolymphocytic leukemia.
  • This life-threatening disorder should be added to the differential diagnosis of eyelid edema.
  • [MeSH-major] Edema / etiology. Eyelid Diseases / etiology. Leukemia, Prolymphocytic / complications. Leukemia, T-Cell / complications. Orbital Diseases / etiology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714934.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC: T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol; 2006 Sep;55(3):467-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
  • BACKGROUND: T-cell prolymphocytic leukemia (T-PLL), formerly categorized as T-cell chronic lymphocytic leukemia, is a rare and aggressive hematologic malignancy.
  • The disease was associated in all with skin involvement with facial preference; edema, purpura, and lesional symmetry were characteristic.
  • All expressed T-cell leukemia 1 (TCL-1) and CD7; cutaneous lymphocyte antigen expression was discernible in a dot-like perinuclear array.
  • In two cases tested, T-cell receptor beta rearrangements were observed.
  • Four patients died from their disease within 18 months of diagnosis.
  • CONCLUSION: T-PLL is a distinctive post-thymic T-cell malignancy with frequent cutaneous tropism.
  • A diagnosis is possible in almost all cases based on characteristic clinical, light microscopic, phenotypic, and cytogenetic features.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Skin / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Aneuploidy. Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / pathology. Cytogenetic Analysis. Face. Female. Gene Amplification. Gene Rearrangement. Glycoproteins / metabolism. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Phenotype. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-myc / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2007 Sep;57(3):533-4 [17707160.001]
  • (PMID = 16908353.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / TCL1A protein, human
  •  go-up   go-down


19. Osuji N, Matutes E, Catovsky D, Lampert I, Wotherspoon A: Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review. Am J Surg Pathol; 2005 Jul;29(7):935-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review.
  • We review retrospectively the spleen histology in 8 patients with T-cell large granular lymphocyte (LGL) leukemia and 4 with T-cell prolymphocytic leukemia (T-PLL) to identify characteristic patterns of involvement and to distinguish such patterns from those described in other low grade B- and T-cell malignancies.
  • Moderate splenic enlargement with red pulp expansion due to lymphocytic infiltration was characteristic of LGL leukemia.
  • Unlike in hairy cell leukemia, the main differential diagnosis for red pulp lymphocytosis, the white pulp was not only preserved in T-cell LGL leukemia but showed germinal center hyperplasia with expansion of the mantle zones.
  • T-cell prolymphocytes did not express cytotoxic granule proteins or NK-cell markers, were CD5+, CD45RO+ like normal spleen T cells, were CD2+, CD3+, CD45+, CD43+, TCRbeta+, but CD25-, CD30-, ALK-1-, TRAP-, DBA44-, and TdT-.
  • These observations on the morphologic and immunohistochemical appearances of the spleen in T-cell LGL leukemia and T-PLL may aid diagnosis of these uncommon T-cell disorders, particularly T-cell LGL leukemia, where presentation may be cryptic and where unique pathognomonic features, are absent.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, T-Cell / pathology. Spleen / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958859.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 23
  •  go-up   go-down


20. Toyota S, Nakamura N, Dan K: Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype. Int J Hematol; 2005 Jan;81(1):66-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype.
  • T-cell prolymphocytic leukemia (T-PLL) is a rare postthymic T-cell disorder.
  • The disease is characterized by lymphadenopathy, splenomegaly, skin lesions, a high white blood cell count, and an aggressive clinical course.
  • The small cell variant of T-PLL occurs in approximately 20% of patients.
  • Most T-PLL patients express membrane T-cell receptors (TCR) of the alphabeta phenotype.
  • The diagnosis of small cell variant T-PLL in a 56-year-old woman was based on the findings of abnormal lymphocytosis, immunophenotype, lymphadenopathy, and aggressive clinical behavior.
  • This case was typical T-PLL except for the morphologically small cell type and the lack of the typical chromosome aberration.
  • If cases accumulate in the future, the specific features of the gamma8 type of T-PLL will become clearer.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, T-Cell / pathology. Receptors, Antigen, T-Cell, gamma-delta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2142-52 [11304766.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):749-51 [11797117.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1792-8 [12419753.001]
  • [Cites] J Exp Med. 1989 Apr 1;169(4):1277-94 [2564416.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Am J Pathol. 1988 Sep;132(3):401-5 [3261945.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):617-28 [1698028.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):753-5 [9674751.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Int J Hematol. 1999 Apr;69(3):186-95 [10222658.001]
  • [Cites] Blood. 1987 Oct;70(4):926-31 [3115337.001]
  • [Cites] Nature. 1984 Apr 26-May 2;308(5962):858-60 [6609313.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1453-5 [8751461.001]
  • (PMID = 15717692.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


21. Robak T, Robak P: Current treatment options in prolymphocytic leukemia. Med Sci Monit; 2007 Apr;13(4):RA69-80
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options in prolymphocytic leukemia.
  • Prolymphocytic leukemia (PLL) is a rare lymphoproliferative disorder characterized by marked leukocytosis and splenomegaly.
  • PLL accounts for approximately 2% of chronic lymphoid leukemias.
  • The clinical course is progressive in the majority of cases due to the resistance of the disease to conventional chemotherapy.
  • The disease is divided according to the cell of origin into the B- (B-PLL) and T-cell (T-PLL) types.
  • Approximately 80% of cases are of B-cell phenotype.
  • PLL has poorer prognosis than chronic lymphocytic leukemia (CLL), and the patients with static disease for a longer period of time are rare.
  • PLL is still considered an incurable disease.
  • Finally, high-dose chemotherapy followed by allogenic or autologous stem cell transplantation seems to be an effective, probably curative, strategy for the treatment of selected patients with PLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Prolymphocytic / diagnosis. Leukemia, Prolymphocytic / drug therapy. Leukemia, Prolymphocytic / genetics. Purine Nucleosides / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Cladribine / therapeutic use. Drug Therapy / methods. Humans. Pentostatin / therapeutic use. Rituximab. Splenectomy / methods. Stem Cell Transplantation / methods. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392661.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Purine Nucleosides; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 118
  •  go-up   go-down


22. Dungarwalla M, Matutes E, Dearden CE: Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol; 2008 Jun;80(6):469-76
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.
  • Prolymphocytic leukaemias of B and T cell subtype are rare diseases.
  • Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor.
  • Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted.
  • Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable.
  • While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphoid / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Disease Progression. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331594.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 49
  •  go-up   go-down


23. Ogasawara T, Narita C, Kawauchi K: Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia. Leuk Res; 2007 Mar;31(3):403-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.
  • We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid.
  • Immunophenotyping of leukemia cells revealed either CD3+CD4+CD8-CD25+ or CD3+CD4+CD8+CD25+.
  • The antibody against human T-cell lymphotropic virus type I was negative.
  • A diagnosis of T-PLL was made.
  • Moreover, polymerase chain reaction analysis demonstrated an expression of VEGF mRNA in the leukemia cells, indicating a production of VEGF from leukemia cells and its involvement in the pathogenesis of T-PLL.
  • [MeSH-major] Leukemia, Prolymphocytic / immunology. Leukemia, T-Cell / immunology. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620970.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


24. de Oliveira FM, Tone LG, Simões BP, Rego EM, Marinato AF, Jácomo RH, Falcão RP: Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia. Int J Lab Hematol; 2009 Aug;31(4):453-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia.
  • We report a case of T-cell prolymphocytic leukemia (T-PLL) in a 41-year-old male.
  • Classical cytogenetic, spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) studies of a blood sample obtained at diagnosis revealed the co-existence of t(X;14)(q28;q11), t(Y;14)(q12;q11) and a ring chromosome derived from i(8)(q10).
  • Immunophenotypic studies revealed involvement of T-cell lineage, with proliferation of CD4(-) CD8+.
  • Chromosomal instability associated with the disease progression may have allowed the emergence of cell clones with translocations involving the sex chromosomes and the ring chromosome observed.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Leukemia, Prolymphocytic, T-Cell / genetics. Ring Chromosomes. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294235.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Madaris L: T-cell prolymphocytic leukemia: A rare disease in an elderly female. J Am Acad Nurse Pract; 2010 Dec;22(12):648-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: A rare disease in an elderly female.
  • This report includes a review of the morphology of T-cell prolymphocytic leukemia (PLL), diagnosis, and the treatment options considered.
  • DATA SOURCES: T-cell PLL is a rare blood disorder that represents a very small number of all chronic leukemias.
  • An extensive review of scientific literature related to the cell morphology and pathology of this disease, as well as clinical trials of treatment options provided the background for this case report.
  • CONCLUSION: A diagnosis of T-cell PLL was made after a computed tomography scan of the abdomen confirmed splenomegaly and a bone marrow biopsy showed a hypercellular marrow infiltrated with numerous small lymphocytes, consistent with this disease.
  • Currently, there is no optimal treatment for T-cell PLL, but alemtuzumab has shown success with extending survival 1-3 years.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 The Author Journal compilation ©2010 American Academy of Nurse Practitioners.
  • (PMID = 21129072.001).
  • [ISSN] 1745-7599
  • [Journal-full-title] Journal of the American Academy of Nurse Practitioners
  • [ISO-abbreviation] J Am Acad Nurse Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


26. Krejcí M, Adam Z, Pour L, Brychtová Y, Mayer J, Vorlícek J: [B-cell chronic lymphocytic leukaemia and the similar states]. Vnitr Lek; 2009 Sep;55(9):746-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-cell chronic lymphocytic leukaemia and the similar states].
  • [Transliterated title] Chronická B-lymfatická leukemie a jí podobné stavy.
  • B-cell chronic lymphocytic leukaemia and the similar diseases are seen predominantly in patients above the age 50 years, i.e. at the age when the patients also have other co-morbidities.
  • The aim of the present review is to provide the medical community with the main information on this disease as patients with B-cell chronic lymphocytic leukaemia and similar disease states are of older age and very often suffer from a range of co-morbidities.
  • The aim of the following text is to present a clear overview of the basic information about this group of diseases that might be useful to all physicians who provide care to patients with B-cell chronic lymphocytic leukaemia and similar conditions.
  • Since monoclonal immunoglobulin is sometimes identified in patients with these diseases, it is important to consider these conditions in the differential diagnosis of the states with the presence of monoclonal immunoglobulin.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukemia, Hairy Cell / diagnosis. Leukemia, Prolymphocytic / diagnosis. Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785372.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 41
  •  go-up   go-down


27. Maljaei SH, Asvadi-E-Kermani I, Eivazi-E-Ziaei J, Nikanfar A, Vaez J: Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders. Indian J Med Sci; 2005 May;59(5):187-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders.
  • BACKGROUND: Although many B-cell chronic lymphoproliferative disorders (BCLPDs) including B-cell chronic lymphocytic leukemia (B-CLL) have characteristic clinical and biological features, the overlapping morphologic and immunophenotypic profiles of various BCLPDs, is still the main problem.
  • MATERIALS AND METHODS: The expression of CD45 in 37 patients with BCLPD including typical B-CLL (Group I), atypical B-CLL and CLL/PLL (II), and hairy cell leukemia (HCL), B-prolymphocytic leukemia (B-PLL), and B-non Hodgkin's lymphoma (B-NHL) as non-CLL BCLPDs (III) and in eight healthy age matched controls (IV) was quantitatively compared by flow cytometric CD45/RALS gating strategy.
  • [MeSH-major] Antigens, CD45 / immunology. Leukemia, B-Cell / diagnosis. Membrane Proteins / biosynthesis. Phosphoproteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Biomarkers / blood. Diagnosis, Differential. Female. Flow Cytometry. Fluorescent Antibody Technique, Direct. Follow-Up Studies. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985726.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PTPRCAP protein, human; 0 / Phosphoproteins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


28. Absi A, Hsi E, Kalaycio M: Prolymphocytic leukemia. Curr Treat Options Oncol; 2005 May;6(3):197-208
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukemia.
  • Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features.
  • T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
  • We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond.
  • Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progression-free-survival with fludarabine.
  • Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / therapy. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / administration & dosage. Female. Humans. Male. Pentostatin / administration & dosage. Rituximab. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):169-79 [10194135.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):145-7 [14508807.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):230-1 [10706770.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):137-9 [11168523.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Acta Haematol. 1999;102(2):94-8 [10529513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):571-81 [11293906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3885-9 [9520462.001]
  • [Cites] Eur J Haematol. 1996 Apr;56(4):235-40 [8641392.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):1-9 [1913594.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):37-43 [8996122.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Ann Hematol. 2004 May;83(5):319-21 [15060751.001]
  • [Cites] Am J Hematol. 1992 May;40(1):71-2 [1566752.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):391-4 [14663643.001]
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):66-70 [1699285.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3555-61 [14506141.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):371-5 [8704689.001]
  • [Cites] Eur J Haematol. 1992 Jul;49(1):46-7 [1499697.001]
  • [Cites] Hematol Pathol. 1987;1(1):27-33 [3509770.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1821 [1357112.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12 Suppl 2:S15-9 [11508932.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):981-7 [11697653.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1284-5 [7738636.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):580 [8790162.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):157-9 [8611452.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] Jpn J Clin Oncol. 1998 Apr;28(4):267-9 [9657013.001]
  • [Cites] Ann Hematol. 1998 Feb;76(2):85-6 [9540763.001]
  • [Cites] Cancer Treat Res. 1993;64:105-19 [7680874.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):114-20 [12491512.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • (PMID = 15869731.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 54
  •  go-up   go-down


29. Moid F, Day E, Schneider MA, Goldstein K, DePalma L: An indolent case of T-prolymphocytic leukemia with t(3;22)(q21;q11.2) and elevated serum beta2-microglobulin. Arch Pathol Lab Med; 2005 Sep;129(9):1164-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An indolent case of T-prolymphocytic leukemia with t(3;22)(q21;q11.2) and elevated serum beta2-microglobulin.
  • We report a novel case of T-prolymphocytic leukemia, small cell variant, associated with complex cytogenetic findings including t(3;22)(q21;11.2) and elevated serum beta2-microglobulin.
  • The diagnosis is based on morphologic, immunophenotypic, cytogenetic, and molecular analysis of peripheral blood and bone marrow.
  • In contrast to most reported cases of T-prolymphocytic leukemia, this patient did not present with lymphadenopathy or organomegaly.
  • In the absence of any specific treatment, the patient is doing well, with a stable white blood cell count 12 months following presentation.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 3 / genetics. Leukemia, Prolymphocytic. Leukemia, Prolymphocytic, T-Cell. Translocation, Genetic / genetics. beta 2-Microglobulin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119992.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta 2-Microglobulin
  •  go-up   go-down


30. Jahanmehr SA, Rogers M, Zheng J, Lai R, Wang C: Quantitation of cytological parameters of malignant lymphocytes using computerized image analysis. Int J Lab Hematol; 2008 Aug;30(4):278-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, image analysis program was used to quantitate cytological parameters of lymphocytes in B-cell lymphoproliferative disorders.
  • Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and B-cell prolymphocytic leukemia (B-PLL) were selected to represent typically small, medium, and large-sized lymphocytes, respectively.
  • A set of measurements was generated for quantitation of total cell area, cell diameter, cytoplasm area, nuclear area, nuclear/cell ratio, and nuclear density.
  • The results from image analysis may assist in defining morphological criteria and in developing quantitative cell morphology.
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic, B-Cell / pathology. Lymphoma, Mantle-Cell / pathology. Microscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665824.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


31. Tarsitano M, Palmieri S, Ferrara F, Riccardi C, Cavaliere ML, Vicari L: Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia. Cancer Genet Cytogenet; 2009 Dec;195(2):164-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
  • The t(11;14)(q13;q32) is a hallmark of mantle cell lymphoma.
  • It has been found less frequently in other lymphoproliferative disorders, such as B-prolymphocytic leukemia, plasma cell leukemia, chronic lymphocytic leukemia, and multiple myeloma.
  • Here, we describe a patient with acute myeloid leukemia (AML), categorized as M5b according to French-American-British classification, in which conventional cytogenetic analysis revealed a karyotype with t(11;14)(q13;q32).
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963117.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


32. Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, Hotta T: [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia]. Rinsho Ketsueki; 2005 Jul;46(7):527-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia].
  • Leukocyte count at diagnosis was 17,900/microl with 58% atypical lymphocytes having a convoluted nucleus and prominent nucleoli.
  • The patient was treated with Ara-C and etoposide before conditioning to decrease the high leukemia burden.
  • Because 9.4% of residual recipient type T-cells was seen with STR analysis on day 22, we decreased the dose of Cs'A.
  • After the occurrence of mild acute GVHD, the residual T-cell number decreased.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Leukemia Effect. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Graft vs Host Disease / prevention & control. Humans. Remission Induction. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440747.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


33. Fidani L, Hatzitolios AI, Goulas A, Savopoulos C, Basayannis C, Kotsis A: Cholesteryl ester transfer protein TaqI B and lipoprotein lipase Ser447Ter gene polymorphisms are not associated with ischaemic stroke in Greek patients. Neurosci Lett; 2005 Aug 12-19;384(1-2):102-5
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholesteryl ester transfer protein (CETP) and lipoprotein lipase (LPL) are both key players in plasma lipoprotein homeostasis and, as such, genetically induced alterations in their respective activities may affect susceptibility to cerebrovascular diseases.
  • In this study, we examined the distribution of two common polymorphisms, namely CETP TaqI B and LPL Ser447Ter in a cohort of Greek clinically diagnosed late-onset ischaemic stroke patients (n = 98) and an ethnicity-, age- and sex-matched control group with no manifestations of vascular disease (n = 100).
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Cholesterol Ester Transfer Proteins. Female. Gene Frequency. Genetic Predisposition to Disease. Greece / epidemiology. Humans. Male. Odds Ratio

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896905.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CETP protein, human; 0 / Carrier Proteins; 0 / Cholesterol Ester Transfer Proteins; 0 / Glycoproteins; 452VLY9402 / Serine; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


34. Gujral S, Polampalli S, Badrinath Y, Kumar A, Subramanian PG, Nair R, Sengar M, Nair C: Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia. Indian J Cancer; 2010 Apr-Jun;47(2):189-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia.
  • INTRODUCTION: Mature T/NK cell lymphomas (MTNKL) presenting as leukemia are rare and show considerable overlapping of clinical, morphological and immunophenotypic features.
  • MATERIALS AND METHODS: We reviewed 380 consecutive cases of mature lymphoid neoplasm that presented as leukemia and were diagnosed on morphology and immunophenotyping of bone marrow and/or peripheral blood samples.
  • MTNKL constituted 4% (nine cases) of all mature lymphoid neoplasms presenting as leukemia.
  • It included four cases of T-large granular leukemia (T-LGL), two of T-cell prolymphocytic leukemia small cell variant (T-PLL), two of adult T-cell leukemia/lymphoma (ATLL) and one of primary cutaneous gamma delta T-cell lymphoma (PCGDTCL).
  • One case of T- PLL small cell variant showed CD4+/CD8- phenotype, while the other revealed CD4-/CD8+ phenotype.
  • CONCLUSION: Mature nodal T/NK cell neoplasms are rare and MTNKL presenting as leukemia are even rarer.
  • There is an overlap between the immunophenotypic profiles of different MTNKL subtypes and elaborate T/NK cell panels are required for their evaluation.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Bone Marrow / immunology. Bone Marrow / pathology. Diagnosis, Differential. Female. Flow Cytometry. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448385.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Dong HY, Weisberger J, Liu Z, Tugulea S: Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. Am J Clin Pathol; 2009 Apr;131(4):586-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics.
  • CD103 is characteristically expressed in hairy cell leukemia (HCL), a B-lymphoproliferative disorder highly responsive to treatment with purine analogs.
  • Other CD103+ diseases are rare and do not respond well to the same therapy, including HCL variant (HCLv) and splenic marginal zone B-cell lymphoma (SMZL) variants.
  • The CD25- cases had variable morphologic features ranging from HCLv and SMZL to prolymphocytic leukemia and diffuse large B-cell lymphoma.
  • Clinically, patients with CD25- disease tended to be older (P= .001), typically had leukocytosis (P= .014), and did not respond well to cladribine or pentostatin.
  • While HCL coexpresses CD25 and annexin-A1, diseases lacking CD25 and annexin-A1 behave clinically differently and can be separated from HCL on diagnosis.
  • [MeSH-major] Antigens, CD / biosynthesis. Integrin alpha Chains / biosynthesis. Interleukin-2 Receptor alpha Subunit / biosynthesis. Leukemia, Hairy Cell / classification. Receptors, Peptide / biosynthesis
  • [MeSH-minor] Diagnosis, Differential. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289595.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Integrin alpha Chains; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Receptors, Peptide; 0 / alpha E integrins; 0 / annexin-A1 receptor, human
  •  go-up   go-down


36. Klobusicka M, Kusenda J, Stevulova L, Kovarikova A, Babusikova O: Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia. Neoplasma; 2010;57(5):429-37
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia.
  • B-cell chronic lymphocytic leukemia (B-CLL) represents a heterogeneous disease with a very variable outcome.
  • The reliable prognosis of this disease at the time of initial diagnosis is difficult to predict.
  • The purpose of this preliminary study was to utilize the nucleolar morphology and to investigate the incidence of main nucleolar types in leukemic lymphocytes in B-CLL patients to assess their possible predictive value for the disease outcome, in correlation with immunophenotype parameters.
  • The evaluation of nucleolar morphology of pathologic lymphocytes was performed at diagnosis and during the course of disease.
  • Median follow up period of patients was 16.4 months (range from 2 to 32 months) from diagnosis.
  • The presence of ring shaped and compact nucleoli in leukemic lymphocytes divided patients into two subgroups with different outcome of the disease.
  • The population of leukemic cells of a small group of B-CLL patients (Group 2, 13 patients, 15.4%) was characterized by the presence of various proportions of pathologic lymphocytes with one large compact nucleolus.Different response to the therapy discriminated the B-CLL patients whose leukemic lymphocytes revealed evident compact nucleoli at presentation, to next two subsets.
  • None of our B-CLL patients had the signs of transformation to prolymphocytic or other type of B cell neoplasms during the follow up.
  • The simplicity and utility of the nucleolar test as a possible prognostic parameter may help to identify the subset of patients with early B-CLL disease that will run a more progressive course.
  • [MeSH-major] Cell Nucleolus / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphocytes / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568897.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


37. Malani AK, Gupta C, Rangineni R, Singh J, Ammar H: Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia. Acta Oncol; 2007;46(2):247-9
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia.
  • T-cell large granular lymphocyte leukemia (T-LGL) also known as T-cell chronic lymphocytic leukemia is rare and comprises a small minority of all small lymphocytic leukemias.
  • The concomitant presentation of T-LGL with acute myeloid leukemia (AML) has not been previously reported.
  • We present an elderly gentleman with concomitant T-LGL and AML (non-M3) diagnosed by a combination of morphologic evaluation, immunophenotyping by flow cytometry, and T-cell gene rearrangement studies.
  • He remains alive and well seven months after initial diagnosis.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Leukemia, Prolymphocytic, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Aged, 80 and over. Antigens, CD / analysis. Flow Cytometry. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453377.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 17
  •  go-up   go-down


38. Dixit M, Choudhuri G, Mittal B: Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study. Hepatol Res; 2006 Sep;36(1):61-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study.
  • INTRODUCTION: To identify high risk alleles for gallstone disease, we analyzed association of LDLRAvaII, LRPAP1 insertion/deletion, CETPTaqI B, and LPLHindIII polymorphisms with gallstone disease.
  • RESULTS: LRPAP1 gene insertion/deletion polymorphism was found to be significantly associated with gallstone disease.
  • Genotype II was conferring significant risk for gallstone disease in females only (P=0.019; OR 2.577, 95% CI 1.144-5.806).
  • LDLRAvaII, CETPTaqI B, and LPLHindIII polymorphisms were not found to be associated with gallstone disease either at genotype or allele level.
  • CONCLUSIONS: LRPAP1, II genotype carrier females may have increased risk for gallstone disease.
  • On the other hand, LDLR AvaII, CETP TaqI B, and LPL HindIII polymorphisms may not be associated with gallstone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837242.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


39. Calfa CJ, Lossos IS, Ruiz P, Davis JL: Ocular involvement as the initial manifestation of T-cell chronic lymphocytic leukemia. Am J Ophthalmol; 2007 Aug;144(2):326-9
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular involvement as the initial manifestation of T-cell chronic lymphocytic leukemia.
  • PURPOSE: To present a case of T-cell chronic lymphocytic leukemia (T-CLL) manifesting as an intraocular lymphoma.
  • Morphologic, immunohistochemical, flow cytometry, and molecular analysis by polymerase chain reaction of vitreous fluid, peripheral blood, bone marrow aspirate, and biopsy were performed.
  • RESULTS: Cytofluorographic and molecular analysis of vitreous cells demonstrated a monoclonal T-cell population consistent with a T-cell intraocular lymphoma.
  • Systemic evaluation established diagnosis of T-cell CLL.
  • CONCLUSION: T-CLL is a rare disease with an aggressive clinical course.
  • We present a case of T-cell intraocular lymphoma as the initial manifestation of an otherwise asymptomatic T-CLL.
  • [MeSH-major] Eye Neoplasms / diagnosis. Leukemia, Prolymphocytic, T-Cell / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. Vitreous Body / pathology
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Biomarkers, Tumor / genetics. Biopsy. Bone Marrow Cells / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Flow Cytometry. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Immunohistochemistry. Pentostatin / therapeutic use. Polymerase Chain Reaction. Tomography, Optical Coherence. Vitrectomy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659976.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 395575MZO7 / Pentostatin
  •  go-up   go-down


40. Takizawa M, Matsushima T, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y: [Unclassified mature T cell leukemia with cerebriform nuclei]. Rinsho Ketsueki; 2005 Jul;46(7):486-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unclassified mature T cell leukemia with cerebriform nuclei].
  • Adult T cell leukemia (ATL) and Sézary syndrome (SS) were ruled out because of the negative HTLV-1 test and the absence of skin lesions, respectively.
  • T-prolymphocytic leukemia (T-PLL), which is characterized by a marked increase in leukocytes having a CD7-phenotype and a progressive fatal course, was also excluded.
  • Recently, the TCL1 onco-protein has been shown to be overexpressed in progressive T-PLL but not in other mature T cell leukemias including Sézary syndrome.
  • In its morphology and phenotypes, our case resembled 'Sézary cell leukemia (SCL)' but the clinical course was much more indolent.
  • This case did not match any of the mature T cell leukemias defined in the WHO classification.
  • [MeSH-major] Cell Nucleus / ultrastructure. Leukemia, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440739.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


41. Narat S, Gandla J, Dogan A, Mehta A: Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma; 2005 Aug;46(8):1229-32
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of hairy cell leukemia variant with rituximab.
  • Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia.
  • We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years.
  • Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cell Count. Humans. Male. Middle Aged. Remission Induction / methods. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085567.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


42. Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien S: Mature T-cell leukemias. Cancer; 2005 Nov 1;104(9):1808-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-cell leukemias.
  • Mature T-cell and NK-cell leukemias are a group of relatively uncommon neoplasms derived from mature or postthymic T-cells accounting for a relatively small percentage of lymphoid malignancies.
  • The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of these disorders from their B-cell counterparts.
  • Herein, we review the clinical and pathological features of mature T-cell leukemias.
  • [MeSH-major] Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Human T-lymphotropic virus 1. Humans. Immunophenotyping. Leukemia, Lymphoid. Leukemia, Prolymphocytic / diagnosis. Leukemia, Prolymphocytic / drug therapy. Leukemia, Prolymphocytic / genetics. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Middle Aged. Tumor Virus Infections

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16136598.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 143
  •  go-up   go-down


43. Li ZQ, Chen HS, Liu EB, Sun Q, Fang LH, Sun FJ, Zhang PH, Yang QY, Qiu LG: [Clinicopathologic study of 15 splenectomy specimens of patients with hairy cell leukemia]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):769-73
Genetic Alliance. consumer health - Hairy Cell Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 15 splenectomy specimens of patients with hairy cell leukemia].
  • OBJECTIVE: To investigate the clinicopathologic features, diagnosis, differential diagnosis and the prognosis of hairy cell leukemia (HCL).
  • The abundant cytoplasm and prominent cell border resulted in a "fried egg" appearance.
  • Definite diagnosis of HCL requires a combined histological and immunohistochemical assessment of the splenectomy specimen, bone marrow biopsy and aspirate.
  • [MeSH-major] Leukemia, Hairy Cell / metabolism. Leukemia, Hairy Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Spleen / pathology. Splenectomy
  • [MeSH-minor] Adult. Aged. Annexin A1 / metabolism. Antigens, CD11c / metabolism. Antigens, CD20 / metabolism. Antigens, CD45 / metabolism. Antigens, CD79 / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic / metabolism. Leukemia, Prolymphocytic / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / metabolism. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079018.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Antigens, CD11c; 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / Ki-67 Antigen; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


44. Cotta CV, Hsi ED: Pathobiology of mature T-cell lymphomas. Clin Lymphoma Myeloma; 2008 Dec;8 Suppl 5:S168-79

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathobiology of mature T-cell lymphomas.
  • Mature T- and natural killer (NK)-cell neoplasms are relatively rare forms of leukemia/lymphoma.
  • The diagnosis of these entities is often difficult, necessitating extensive immunophenotypic, molecular, and genetic testing.
  • This article presents an updated view of the morphologic, immunophenotypic, genetic, and molecular characteristics of the mature T- and NK-cell neoplasms.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Humans. Immunoblastic Lymphadenopathy / diagnosis. Killer Cells, Natural / physiology. Leukemia, Large Granular Lymphocytic / diagnosis. Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. T-Lymphocytes / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073524.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 129
  •  go-up   go-down


45. Matutes E, Wotherspoon A, Catovsky D: Differential diagnosis in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol; 2007 Sep;20(3):367-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis in chronic lymphocytic leukaemia.
  • The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features.
  • In cases with atypical features, these investigations should be complemented with cytogenetics and/or histology to confirm the diagnosis and to exclude other B-cell disorders.
  • Cell-marker studies provide a robust foundation to establish the diagnosis as the lymphocytes have a distinct immunophenotypic signature.
  • Although no single antigen is exclusively expressed in CLL cells, when several markers are compounded into a scoring system the results allow firming up of the diagnosis.
  • Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Diagnosis, Differential. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Leukemia, Hairy Cell / diagnosis. Leukemia, Prolymphocytic / diagnosis. Lymphocytes / pathology. Prognosis. Spleen / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707827.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Marx A, Müller-Hermelink HK, Hartmann M, Geissinger E, Zettl A, Adam P, Rüdiger T: [Lymphomas of the spleen]. Pathologe; 2008 Mar;29(2):136-42
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exceptions include splenic marginal zone lymphomas and hepatosplenic T-cell lymphomas that are typically diagnosed from histological findings.
  • In addition, hairy-cell leukemia, LGL leukemia and T-cell prolymphocytic leukemia typically show characteristic patterns of infiltration in the spleen which may be diagnostically useful.
  • [MeSH-minor] Antigens, CD / analysis. Diagnosis, Differential. Humans. Leukemia, Hairy Cell / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Lymphoma, T-Cell / pathology. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 15;102(13):4261-9 [12907441.001]
  • [Cites] Semin Diagn Pathol. 2003 May;20(2):105-20 [12945934.001]
  • [Cites] Histol Histopathol. 1990 Jan;5(1):113-22 [2134351.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):772-80 [9236833.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Semin Diagn Pathol. 2003 May;20(2):121-7 [12945935.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):935-41 [15958859.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):763-71 [12875995.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4265-74 [8943863.001]
  • [Cites] Semin Diagn Pathol. 2003 May;20(2):84-93 [12945932.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1581-92 [11117778.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):81-8 [12107092.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] Int J Surg Pathol. 2004 Jan;12(1):31-7 [14765270.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2001-9 [11391578.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):895-902 [12826881.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):62-8 [2912876.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Leuk Lymphoma. 1994;14 Suppl 1:1-12 [7820038.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):757-65 [2504066.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):643-51 [2661408.001]
  • [Cites] Histopathology. 1998 Sep;33(3):230-9 [9777389.001]
  • (PMID = 18214484.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


47. Martinez-Gallo M, Puy C, Ruiz-Hernandez R, Rodriguez-Arias JM, Bofill M, Nomdedeu JF, Cigudosa JC, Rodriguez-Sanchez JL, de la Calle-Martin O: Severe and recurrent episodes of bronchiolitis obliterans organising pneumonia associated with indolent CD4+ CD8+ T-cell leukaemia. Eur Respir J; 2008 Jun;31(6):1368-72
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe and recurrent episodes of bronchiolitis obliterans organising pneumonia associated with indolent CD4+ CD8+ T-cell leukaemia.
  • It can mimic infectious pneumonia but diagnosis is suspected when there is no response to multiple antibiotic treatment, and blood and sputum cultures are negative for microorganisms.
  • However, T-cell receptor Vbeta chain analysis indicated clonal rearrangement, and cytogenetic studies displayed chromosomic alterations that were similar to clonal proliferation observed in ataxia-telangiectasia and T-prolymphocytic leukaemia.
  • [MeSH-major] Cryptogenic Organizing Pneumonia / complications. Leukemia, T-Cell / complications. Leukemia, T-Cell / diagnosis

  • Genetic Alliance. consumer health - Bronchiolitis Obliterans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515560.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


48. Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJ, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue MH, Kneba M, van Dongen JJ, Beldjord K, Molina TJ: Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia; 2007 Feb;21(2):215-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.
  • Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms.
  • To obtain reference values for Ig/TCR rearrangement patterns, 19 European laboratories investigated 188 T-cell malignancies belonging to five World Health Organization-defined entities.
  • TCR clonality was detected in 99% (143/145) of all definite cases of T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma (unspecified) and angioimmunoblastic T-cell lymphoma (AILT), whereas nine of 43 anaplastic large cell lymphomas did not show clonal TCR rearrangements.
  • Our study indicates that the BIOMED-2 multiplex PCR tubes provide a powerful strategy for clonality assessment in T-cell malignancies assisting the firm diagnosis of T-cell neoplasms.
  • The detected TCR gene rearrangements can also be used as PCR targets for monitoring of minimal residual disease.
  • [MeSH-major] Genes, Immunoglobulin. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics. Polymerase Chain Reaction / methods. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Gene Amplification. Gene Rearrangement. Genotype. Humans. Immunohistochemistry. Leukemia, Prolymphocytic / genetics. Leukemia, Prolymphocytic / immunology. Leukemia, Prolymphocytic / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170730.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


49. Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW: T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules. Am J Clin Pathol; 2005 Dec;124(6):937-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules.
  • T-cell large granular lymphocyte (T-LGL) leukemias represent monoclonal T-cell expansions that express CD16, CD56, or CD57 and cause cytopenias.
  • The identification of T-LGL leukemias can be difficult because reactive T-LGL cells also can express CD16, CD56, and CD57, and many leukemia cases show only mild lymphocytoses.
  • In this study, 23 T-LGL leukemia cases were analyzed by 3- and 4-color flow cytometry to identify markers that could aid in discriminating leukemic from normal T-LGL.
  • In most cases (18/23), abnormalities (bright, dim, or negative expression) of 2 or more pan-T-cell antigens were identified, with all cases showing abnormal CD5 levels.
  • These studies help define abnormal phenotypic features typical of T-LGL leukemia that may have important diagnostic value.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / metabolism. Biomarkers, Tumor / analysis. Histocompatibility Antigens Class I / metabolism. Leukemia, Prolymphocytic, T-Cell / diagnosis. Receptors, Antigen, T-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD5 / metabolism. Female. Flow Cytometry. Humans. Immunophenotyping. Killer Cells, Natural / metabolism. Male. Middle Aged. NK Cell Lectin-Like Receptor Subfamily D / metabolism. Receptors, Immunologic / metabolism. Receptors, KIR. Receptors, KIR2DL1. Receptors, KIR2DL2. Receptors, KIR2DL3. Receptors, KIR3DL1. Receptors, KIR3DL2. T-Lymphocytes / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416744.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class I; 0 / KIR2DL2 protein, human; 0 / NK Cell Lectin-Like Receptor Subfamily D; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR2DL1; 0 / Receptors, KIR2DL2; 0 / Receptors, KIR2DL3; 0 / Receptors, KIR3DL1; 0 / Receptors, KIR3DL2
  •  go-up   go-down


50. Schweighofer CD, Fätkenheuer G, Staib P, Hallek M, Reiser M: Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis. Onkologie; 2007 Nov;30(11):564-6
MedlinePlus Health Information. consumer health - Meningitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis.
  • BACKGROUND: Involvement of the central nervous system (CNS) is a rare complication of chronic lymphocytic leukemia (CLL) and seems to be more frequent in patients with Richter's syndrome or prolymphocytic transformation.
  • PATIENT AND METHODS: We present the case of a 75-year-old male patient who was admitted to a rural hospital with ataxia, disorientation, and signs of progressive CLL disease.
  • RESULTS: When referred to our center, careful immunophenotyping of the CNS lymphocytes as well as assessment for infectious causes of lymphocytic meningitis led to the diagnosis of Lyme disease/neuroborreliosis.
  • CONCLUSION: In conclusion, this case report should alert clinicians that lymphocytic meningeal involvement in CLL patients accounts for the rare leukemic meningeosis only if cerebrospinal fluid cells show a predominating immunophenotype of typical BCLL cells, i.e. by flow cytometry, and if any infectious cause including Lyme disease has been ruled out.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lyme Disease / complications. Lyme Disease / diagnosis. Meningitis / complications. Meningitis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged


51. Matutes E: Adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1373-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukaemia/lymphoma.
  • Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution.
  • The disease manifests with leukaemia in greater than two thirds of patients, while the remaining patients have a lymphomatous form.
  • According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma.
  • Organomegaly, skin involvement, circulating atypical lymphocytes ("flower" cells) with a CD4+ CD25+ phenotype and hypercalcaemia are the most common disease features.
  • The diagnosis should be based on a constellation of clinical features and laboratory investigations.
  • The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), Sézary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease.
  • Despite major advances in understanding the pathogenesis of the disease, management of these patients remains a challenge for clinicians as they do not respond or achieve only transient responses to therapies used in high-grade lymphomas.
  • The use of antiretroviral agents such as zidovudine in combination with interferon-alpha, with or without concomitant chemotherapy, has shown activity in this disease with improvement in survival and response rate.
  • Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunophenotyping. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):65-72 [2578441.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):94-5 [2885585.001]
  • [Cites] Blood. 1987 Nov;70(5):1554-64 [2889485.001]
  • [Cites] Blood. 1988 Apr;71(4):1027-32 [2895676.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):987-90 [1977015.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):76-7 [1670727.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1622-8 [2001551.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1834-7 [7967729.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Leukemia. 1995 Apr;9(4):594-7 [7723390.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):615-9 [7734362.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):459-64 [7549838.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):511-5 [16098064.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):637-40 [10609805.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1392-6 [18042695.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Am J Hematol. 2004 Jun;76(2):187-9 [15164389.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • (PMID = 18042693.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 42
  • [Other-IDs] NLM/ PMC2095573
  •  go-up   go-down


52. Su XY, Xu X, Tang Y, Li GD: [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):542-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases].
  • METHODS: The cytospin preparations/smears and cell block sections of effusion cytology specimens from 33 cases of hematolymphoid malignancy were retrospectively reviewed.
  • In selected cases, in-situ hybridization for Epstein-Barr virus-encoded RNA and immunoglobulin and T-cell receptor gene rearrangement study were carried out as indicated.
  • RESULTS: There were 33 cases of hematolymphoid malignancy, including 12 cases of T-lymphoblastic leukemia/lymphoma, 16 cases of mature B cell neoplasm (including 9 cases of diffuse large B-cell lymphoma, 2 cases of Burkitt lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma and 1 case of mantle cell lymphoma), 3 cases of mature T or NK-cell neoplasm (including 1 case of extranodal nasal NK/T-cell lymphoma, 1 case of angioimmunoblastic T-cell lymphoma and 1 case of T-cell prolymphocytic leukemia), 1 case of myeloid sarcoma and 1 case of mast cell sarcoma.
  • Amongst the 33 cases studied, 16 represented disease relapses, including 8 cases of diffuse large B-cell lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma, 1 case of T-lymphoblastic leukemia/lymphoma, 1 case of angioimmunoblastic T-cell lymphoma, 1 case of mantle cell lymphoma and 1 case of mast cell sarcoma.
  • The remaining 17 cases showed serous effusion as the primary manifestation, with the diagnosis primarily made upon cytologic examination.
  • The cytologic findings seen in all the 33 cases studied were in agreement with the corresponding histologic diagnosis.
  • CONCLUSIONS: Diagnosis of hematolymphoid malignancy by effusion fluid cytology specimens is possible, especially when coupled with the clinical history, immunophenotype, in-situ hybridization and gene rearrangement study findings.
  • This is especially so for cases with disease relapses.
  • [MeSH-major] Ascitic Fluid / pathology. Cytodiagnosis / methods. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunohistochemistry. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Plasmacytoma / diagnosis. Plasmacytoma / metabolism. Plasmacytoma / pathology. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021966.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Troussard X, Cornet E: Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes. Curr Treat Options Oncol; 2007 Apr;8(2):97-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SLVL is a rare leukemic and indolent B-cell chronic lymphoproliferative disorder (B-CLPD) that we have to differentiate from hairy cell leukemia (HCL), B prolymphocytic leukemia (B-PLL) and follicular lymphoma (FL).
  • However, the diagnosis can be difficult to make on morphological criteria, especially in patients without absolute lymphocytosis.
  • SLVL has a relatively clinical benign course but a few patients could require treatment, because of a symptomatic splenomegaly and/or a severe cytopenia.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma, B-Cell / therapy. Splenic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):41-7 [12141954.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1950-6 [10706860.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1558-62 [8123845.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):575-7 [1355156.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):759-64 [12614206.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):712-21 [9674745.001]
  • [Cites] Br J Haematol. 1998 Mar;100(3):609 [9504654.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2050-7 [15389479.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):158-61 [9359516.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):513-7 [16049984.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):404-12 [12877667.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):392-8 [16480431.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1603-7 [7888678.001]
  • [Cites] Eur J Haematol. 2002 Aug;69(2):112-4 [12366716.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2727-37 [14630827.001]
  • [Cites] J Clin Pathol. 1992 Dec;45(12):1111-3 [1479039.001]
  • [Cites] J Clin Pathol. 1987 Jun;40(6):642-51 [3497180.001]
  • [Cites] Leuk Res. 1996 Nov-Dec;20(11-12):909-13 [9009248.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1212-3 [9886348.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):600-4 [10086800.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):731-6 [8652403.001]
  • [Cites] Haematologica. 2005 Apr;90(4):470-8 [15820942.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jan;36(1):57-69 [12461750.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1736-40 [9563492.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):487-91 [8136270.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jul 1;96(1):13-6 [9209463.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2659-61 [12239182.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):113-7 [11426611.001]
  • [Cites] Int J Hematol. 2005 Jun;81(5):413-6 [16158822.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 Mar-Apr;91(2):171-4 [9196759.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Blood Rev. 2005 Jan;19(1):39-51 [15572216.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):206-9 [2064958.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):134-40 [16405434.001]
  • [Cites] Leukemia. 2000 Apr;14(4):573-5 [10764141.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1924-5 [15385943.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):130-5 [16000129.001]
  • (PMID = 17634839.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


54. Marie I, Robaday S, Kerleau JM, Jardin F, Levesque H: Typhlitis as a complication of alemtuzumab therapy. Haematologica; 2007 May;92(5):e62-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is an effective immunotherapeutic agent in patients with malignancies such as non-Hodgkin lymphoma, B cell chronic lymphocytic leukemia and T cell pro- lymphocytic leukemia.
  • We recently observed a case of particular interest as the patient with T cell prolymphocytic leukaemia treated with alemtuzumab, exhibited symptomatic reactivation of CMV infection and developed subsequently typhlitis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Typhlitis / diagnosis. Typhlitis / etiology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Female. Humans. Leukemia, Prolymphocytic / immunology. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / immunology. Leukemia, T-Cell / therapy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562596.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


55. Anand M, Sharma S, Kumar R, Raina V: Diagnostic considerations in prolymphocytes in pleural fluid: a case report. Acta Cytol; 2008 Mar-Apr;52(2):251-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prolymphocytes are nucleolated cells that are the defining features of the 2 chronic lymphoproliferative disorders, prolymphocytic leukemia (PLL) and chronic lymphocytic leukemia (CLL) with increased prolymphocytes.
  • Prolymphocytes appear relatively unfamiliar in cytopathology practice, and, particularly when present in body fluids, may resemble blasts or adult T-cell leukemia/ lymphoma (ATLL) cells.
  • CASE: A 32-year-old man, referred to us with a diagnosis of acute leukemia, presented with shortness of breath for 2 months and loss of appetite for 3 months.
  • Better awareness among cytopathologists about prolymphocytes and the disease states in which they occur, as well as insistence, in a clinical setting of leukemia, on interpreting the pleural fluid in relation to the clinical and laboratory findings, especially those of the peripheral blood and bone marrow, can prevent misdiagnosis.
  • [MeSH-major] Diagnostic Errors / prevention & control. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Pleural Effusion, Malignant / pathology. Precursor Cells, T-Lymphoid / pathology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500006.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Bench AJ, Erber WN, Follows GA, Scott MA: Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. Int J Lab Hematol; 2007 Aug;29(4):229-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The demonstration of a clonal immunoglobulin or T cell receptor gene rearrangement offers a useful diagnostic tool in cases where the diagnosis is equivocal.
  • Molecular genetic detection of other genomic rearrangements may not only assist with the diagnosis but can also provide important prognostic information.
  • Many of these rearrangements can act as molecular markers for the detection of low levels of residual disease.
  • [MeSH-major] Lymphoma, B-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Burkitt Lymphoma / genetics. Gene Rearrangement. Humans. Immunoglobulin G / genetics. Leukemia, Hairy Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / genetics. Molecular Diagnostic Techniques. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617076.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 317
  •  go-up   go-down


57. Babadoko AA, Hassan A, Ahmed AJ, Isah HA, Suleiman AM: Splenic lymphoma with villous lymphocytes: case report and literature review. Niger J Med; 2007 Jan-Mar;16(1):71-3
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Splenic lymphoma with villous lymphocytes (SLVL) is a rare but recognized distinct disease entity among chronic B lymphoproliferative disorders.
  • It is frequently misdiagnosed as chronic lymphocytic leukaemia, (CLL) Prolymphocytic leukaemia or Hairy Cell leukaemia.
  • METHOD: The case records of a sixty year old Nigerian male with a splenic lymphoma and a review of the literature on the subject using MEDLINE, other internet sources and manual library search was utilized.
  • CONCLUSION: Adequate morphologic evaluation is advocated particularly in the resource limited settings were Cytogenetics, immunohistochemistry and immunophenotyping are not available.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma / diagnosis. Lymphoproliferative Disorders / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563973.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 9
  •  go-up   go-down


62. Mod H, Prasiko G, Jha AK, Chaurasia PP, Srivastava R: Radiotherapy for splenomegaly. JNMA J Nepal Med Assoc; 2005 Jul-Sep;44(159):97-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Massive splenomegaly may be seen in CML, CLL, hairy cell leukemia and splenic marginal zone lymphomas, prolymphocytic leukemia, myeloproliferative disorders such as polycythaemia rubra, polycythaemia vera or essential thrombocytosis or myelofibrosis.
  • [MeSH-major] Brachytherapy. Palliative Care. Primary Myelofibrosis / diagnosis. Splenomegaly / radiotherapy

  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554863.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


63. Mikaelsson E, Danesh-Manesh AH, Lüppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, Mellstedt H, Rabbani H: Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood; 2005 Jun 15;105(12):4828-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
  • Fibromodulin is an extracellular matrix protein normally produced by collagen-rich tissues; the fibromodulin gene has been found to be the most overexpressed gene in B-cell chronic lymphocytic leukemia.
  • In this study, fibromodulin was expressed at the gene level (reverse transcription-polymerase chain reaction [RT-PCR]) in all patients with B-CLL (n = 75) and in most (5 of 7) patients with mantle cell lymphoma (MCL).
  • Fibromodulin was also detected at the protein level in the cytoplasm of the B-CLL cells and in the supernatant after in vitro cultivation, but not at the cell surface.
  • Fibromodulin was not found in patients with T-cell chronic lymphocytic leukemia (T-CLL), B-cell prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), hairy cell leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or chronic myelogenous leukemia (CML) or in 36 hematologic cell lines.
  • [MeSH-major] Extracellular Matrix / metabolism. Extracellular Matrix Proteins / chemistry. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Mantle-Cell / metabolism. Proteoglycans / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, T-Lymphocyte / biosynthesis. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line, Transformed. Cell Line, Tumor. Coculture Techniques. Collagen / metabolism. Cytoplasm / metabolism. DNA Mutational Analysis. DNA, Complementary / metabolism. Female. Fibroblasts / metabolism. Flow Cytometry. Hematologic Neoplasms / metabolism. Humans. Immunoblotting. Lectins, C-Type. Leukemia, T-Cell / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Mutation. Palatine Tonsil / metabolism. RNA, Messenger / metabolism. Receptors, Interleukin-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tetradecanoylphorbol Acetate / pharmacology. Time Factors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741214.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD69 antigen; 0 / DNA, Complementary; 0 / Extracellular Matrix Proteins; 0 / Lectins, C-Type; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / Receptors, Interleukin-2; 126468-95-9 / fibromodulin; 9007-34-5 / Collagen; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


64. Del Giudice I, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, Messina M, Morgan G, Catovsky D, Matutes E: B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia; 2009 Nov;23(11):2160-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic, B-Cell / genetics


65. Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C: A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol; 2009 Jan;88(1):85-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols. Leukemia, Prolymphocytic, B-Cell / drug therapy. Mitoxantrone. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654781.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


66. Pamuk GE, Puyan FO, Unlü E, Oztürk E, Demir M: The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication. Leuk Res; 2009 Jun;33(6):864-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication.
  • [MeSH-major] Central Nervous System Diseases / complications. Leukemia, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929411.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


67. Chaar BT, Petruska PJ: Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol; 2007 May;82(5):417
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. B-Lymphocytes / pathology. Combined Modality Therapy. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160995.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


68. Sandberg Y, Wu KL, Heule F, van den Bos RR, Lam KH, Langerak AW, van der Velden VH, van Lom K, Beverloo HB: Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach. Haematologica; 2007 Mar;92(3):e34-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 6 / ultrastructure. Interdisciplinary Communication. Leukemia, Prolymphocytic / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. T-Lymphocytes / ultrastructure. Translocation, Genetic
  • [MeSH-minor] Antigens, Neoplasm / analysis. B-Lymphocytes / ultrastructure. Biopsy. Bone Marrow / pathology. Diagnostic Errors. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Lichen Nitidus / diagnosis. Male. Middle Aged. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405754.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


69. Gallipoli P, Clark A, Leach M: The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia. Am J Hematol; 2009 Nov;84(11):750-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714590.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Shimizu D, Nomura K, Matsumoto Y, Nishida K, Taki T, Horiike S, Inaba T, Fujita N, Taniwaki M: Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation. Leuk Lymphoma; 2006 Jun;47(6):1170-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / immunology. Fatal Outcome. Female. Humans. Immunophenotyping. Lymphocytes / metabolism. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840216.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


71. Abraham S, Braun RP, Matthes T, Saurat JH: A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia. Br J Dermatol; 2006 Sep;155(3):633-4
MedlinePlus Health Information. consumer health - Eyelid Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia.
  • [MeSH-major] Dermatitis, Allergic Contact / diagnosis. Eyelid Diseases / diagnosis. Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fatal Outcome. Female. Humans. Leukemic Infiltration / diagnosis. Pseudolymphoma / diagnosis. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2000 Aug;143(2):411-4 [10951155.001]
  • (PMID = 16911299.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


72. McElreath DP, Angtuaco TL, Staggs B, Malik AH: T cell prolymphocytic leukemia: a rare cause of acute liver failure. Dig Dis Sci; 2006 Apr;51(4):819-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell prolymphocytic leukemia: a rare cause of acute liver failure.
  • [MeSH-major] Leukemia, Prolymphocytic / complications. Leukemia, Prolymphocytic / diagnosis. Liver Failure, Acute / etiology. Multiple Organ Failure / diagnosis
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Liver Function Tests. Male. Middle Aged. Rare Diseases. Risk Assessment. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology. 2003 Feb;8(1):1-6 [12623420.001]
  • [Cites] Hawaii Med J. 1998 Jan;57(1):372-4 [9509739.001]
  • [Cites] Liver. 2001 Aug;21(4):287-92 [11454193.001]
  • [Cites] J Clin Gastroenterol. 1990 Aug;12(4):441-6 [2204655.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1400-5 [9246036.001]
  • [Cites] Ann Intern Med. 2002 Dec 17;137(12):947-54 [12484709.001]
  • [Cites] Pathol Res Pract. 1998;194(11):781-9 [9842637.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):633-7 [10953986.001]
  • [Cites] N Engl J Med. 1993 Dec 16;329(25):1862-72 [8305063.001]
  • [Cites] Hepatology. 1983 May-Jun;3(3):428-32 [6573294.001]
  • (PMID = 16615010.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. de Lavallade H, Faucher C, Fürst S, El-Cheikh J, Vey N, Coso D, Bouabdallah R, Stoppa AM, Gastaut JA, Blaise D, Mohty M: Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplant; 2006 Apr;37(7):709-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission.
  • [MeSH-major] Graft vs Tumor Effect. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Follow-Up Studies. Graft vs Host Disease / diagnosis. Graft vs Host Disease / therapy. HLA Antigens / analysis. Humans. Male. Prednisone / therapeutic use. Remission Induction. Siblings. Time Factors. Tissue Donors. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474410.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


74. Vassallo J, Huguet F, Brousset P: "In situ" detection of human cytomegalovirus infection of bone marrow in a patient previously treated for B-prolymphocytic leukaemia. J Clin Pathol; 2007 Jul;60(7):839-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "In situ" detection of human cytomegalovirus infection of bone marrow in a patient previously treated for B-prolymphocytic leukaemia.
  • [MeSH-major] Bone Marrow Diseases / diagnosis. Cytomegalovirus Infections / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Prolymphocytic / drug therapy. Opportunistic Infections / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Soc Bras Med Trop. 2001 Jul-Aug;34(4):365-8 [11562730.001]
  • [Cites] South Med J. 1979 Apr;72(4):500-1 [219548.001]
  • [Cites] Lancet Infect Dis. 2004 Dec;4(12):725-38 [15567122.001]
  • [Cites] Ann Hematol. 1992 Jun;64 Suppl:A125-7 [1322181.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1):108-12 [10396292.001]
  • [Cites] Arch Pathol Lab Med. 1982 Mar;106(3):115-8 [6277271.001]
  • (PMID = 17596552.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1995774
  •  go-up   go-down


75. Onishi T, Tamura S, Onishi S: A case of adult T-cell leukemia with colon involvement. Gastrointest Endosc; 2007 Apr;65(4):712-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adult T-cell leukemia with colon involvement.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis. Sigmoid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383471.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Castagna L, Sarina B, Todisco E, Mazza R, Santoro A: Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant; 2005 Jun;35(12):1225
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation / adverse effects. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Autoimmune Diseases / etiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Salvage Therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


77. Morales M, Trujillo M, del Carmen Maeso M, Piris MA: Thymoma and progressive T-cell lymphocytosis. Ann Oncol; 2007 Mar;18(3):603-4
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymoma and progressive T-cell lymphocytosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074971.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


78. Bain BJ, Fawcett N: A T-lineage neoplasm-Which one? Am J Hematol; 2009 Oct;84(10):678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, Neoplasm / analysis. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Humans. Immunophenotyping. Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / immunology. Leukemia, Prolymphocytic, T-Cell / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373891.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Shimoda T, Aoki M, Takezaki S, Futagami A, Inokuchi K, Sugisaki Y, Kawana S: A case of erythrodermic-CTCL. Leuk Lymphoma; 2006 Aug;47(8):1708-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Sezary Syndrome / diagnosis
  • [MeSH-minor] Aged. Biopsy. Dermatitis, Exfoliative / diagnosis. Dermatitis, Exfoliative / pathology. Diagnosis, Differential. Female. Humans. Immunophenotyping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966295.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


80. Dimeski G, Bird R: Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis. Clin Chem Lab Med; 2009;47(7):880-1
Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis.

  • MedlinePlus Health Information. consumer health - Potassium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575549.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gases; RWP5GA015D / Potassium
  •  go-up   go-down


81. Berz D, Freeman NJ: Extreme hyperlymphocytosis. J Clin Oncol; 2008 Feb 1;26(4):674-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / complications. Leukemia, Prolymphocytic, T-Cell / diagnosis. Lymphocytosis / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement